Skip to main content

Table 2 Treatment-related adverse events

From: Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis

Toxicity

All

%

Gr. 3–4

%

Diarrhea

32

62.7

1

2.0

Rash, skin

22

43.1

2

3.9

Mucositis

16

31.4

2

3.9

Paronychia

12

23.5

0

0.0

Weight loss

5

9.8

0

0.0

AST/ALT

4

7.8

0

0.0

Fatigue

4

7.8

0

0.0

Malaise

3

5.9

0

0.0

Fever

2

3.9

0

0.0

Edema, face

1

2.0

0

0.0

Nausea

1

2.0

0

0.0

Thrombocytopenia

1

2.0

0

0.0

Pneumonitis

1

2.0

1

2.0